Pulmonary tuberculosis incidence and drug resistance-related factors analysis in North China

Clicks: 352
ID: 91169
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #2 of 2 articles by views in biomedical and biotechnology research journal

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Background: This study analysis the epidemiological characteristics of incidence, gender, age, occupation, educational level, income, residence location, and timescale of 773 pulmonary tuberculosis patients in Hulin County in North China from 2014 to 2016. Methods: Two hundred and sixty-seven strains were identified and nine drug sensitivity tests against isoniazid (INH), streptomycin (S), ethambutol (EMB), rifampicin (RFP), ofloxacin (OFX), capreomycin, prothionamide, para-aminosalicylic acid (PAS), and kanamycin. Results: The top five drug resistance sequences of nine kinds of anti-TB drugs were S (24.535%) >INH (13.383%) >RFP (8.178%) >OFX (4.089%) >EMB (1.859%). Conclusion: The anti-TB medicine needs to be use under the guidelines to minimize drug resistance, and the elder age and poor also the work focus in the future.
Reference Key
qi2019pulmonarybiomedical Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Qi, Zheng;Yang, Wei;Wang, Yan-Fu;Liu, Chang;
Journal biomedical and biotechnology research journal
Year 2019
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.